## STE: STERIS plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.7% below STRENGTH zone (3.0-6.0%); PEG 1.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($246.01)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Coho Partners Ltd. Sells 16,120 Shares of STERIS plc $STE**
- Source: MarketBeat | 20251223T094626 | Bullish | Relevance: 100%
- Coho Partners Ltd. has reduced its stake in STERIS plc by 13.1%, selling 16,120 shares and now owning 106,865 shares worth approximately $26.44 million. Other institutional investors have also adjusted their positions in STERIS. Several insiders recently sold a significant number of shares, while Wall Street analysts maintain a "Moderate Buy" consensus rating with an average target price of $273.50.

**2. Congress Asset Management Co. Raises Stock Holdings in STERIS plc $STE**
- Source: MarketBeat | 20251222T090453 | Somewhat-Bullish | Relevance: 100%
- Congress Asset Management Co. has increased its stake in STERIS plc (NYSE:STE) by 8.4% in the third quarter, now owning 133,224 shares valued at $32.965 million. Other institutional investors have also adjusted their positions in the medical equipment provider. STERIS announced a quarterly dividend of $0.63 per share, with recent insider selling activity, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $273.50.

**3. Former Steris CEO takes board role at California medical device company**
- Source: Crain's Cleveland Business | 20251223T180741 | Somewhat-Bullish | Relevance: 73%
- Walter M. Rosebrough Jr., former CEO of Steris plc, has been appointed as an independent director at CooperCompanies (Nasdaq: COO), a California-based medical device company. This appointment follows a cooperation agreement with activist investor Browning West LP, which urged changes due to alleged underperformance. Rosebrough is also being considered for the board chair position by the end of 2026, and his proven track record is expected to enhance long-term shareholder value.

**4. CooperCompanies appoints Walt Rosebrough to board in deal with Browning West**
- Source: Investing.com India | 20251223T132751 | Somewhat-Bullish | Relevance: 72%
- CooperCompanies (NASDAQ:COO) has appointed Walter "Walt" M. Rosebrough, Jr. as an independent director, effective January 3, 2026, following a cooperation agreement with Browning West, LP. Rosebrough, CEO Emeritus of STERIS plc, will join the Corporate Governance & Nominating Committee, with consideration for him to become Chair by the end of 2026. This move comes as CooperCompanies' stock has gained 20.6% over the past six months, reflecting recent financial outperformances and positive analyst revisions.

**5. IV Dressing Market Set for Dynamic Rise with Key Players Becton, Dickinson and Company, Lohmann & Rauscher, Komal Health Care Pvt. Ltd.**
- Source: openPR.com | 20251222T090902 | Somewhat-Bullish | Relevance: 65%
- The IV Dressing Market is projected to grow from USD 881.5 million in 2025 to USD 1,265.4 million by 2032, exhibiting a CAGR of 5.3%, driven by increasing industry demand and technological advancements. A new report by Coherent Market Insights details this growth, identifying key players like Becton, Dickinson and Company and 3M, and providing comprehensive analysis across product types, applications, end-users, and regions. The study offers actionable insights for strategic decision-making, covering market dynamics, competitive landscapes, and future opportunities.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.73 elevated, pricing in significant growth expectations. Forward P/E 22.9x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $25.2B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.73 |
| Forward P/E | 22.9 |
| Current P/E | 25.0 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -0.7% (minimal 5-day change). Below STRENGTH zone by 3.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.57), momentum weakening. RSI neutral at 50. OFD pattern: +SUL (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.74% (CS: 56) | Neutral |
| RSI_14 | 49.6 | Neutral |
| MACD Histogram | -0.57 | Bearish |
| vs SMA20 | 0.992x | Below |
| vs SMA50 | 1.010x | Above |
| vs SMA200 | 1.066x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $255.49
- **Stop Loss:** $246.01 (3.7% risk)
- **Target:** $264.97 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 126
- **Position Value:** $32,191.74
- **Portfolio %:** 32.19%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite supported by year-end positioning. VIX at cycle lows (13.47) and multiple sectors hitting 52-week highs indicate constructive sentiment, though breadth at 57.9% suggests selectivity remains important. Fed pause expectations and stable macro backdrop support risk assets.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*